Biogen Inc to Discuss Aducanumab Phase 3 Topline Results at AAN Presentation Transcript
Hello. My name is Samantha Budd Haeberlein. And on behalf of the authors listed here, I'm going to take you through a presentation of EMERGE and ENGAGE topline result, which were 2 Phase III studies to evaluate aducanumab in patients with early Alzheimer's disease.
This presentation may include forward-looking statements.
The aducanumab Phase III studies called EMERGE and ENGAGE were 2 identical 18-month duration, randomized, double-blind, placebo-controlled Phase III studies. They enrolled 3,285 patients at 348 sites in 20 countries which are listed to the right. The population study were early Alzheimer's disease, which included subjects with MCI due to Alzheimer's disease and mild Alzheimer's disease dementia.
There were 2 dosing regimens, a low and a high dosing
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
